The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

REFILE-UPDATE 4-AstraZeneca hitches ride with Russia's Sputnik in vaccine race

Fri, 11th Dec 2020 09:27

(Refiles to fix a typographical error in paragraph 12)

* Trial to start by the end of the year - Russia's RDIF

* Boost for Russian vaccine, which has been criticised in
West

* Once COVID-19 vaccine frontrunner, AstraZeneca has slipped
back

By Andrew Osborn and Pushkala Aripaka

Dec 11 (Reuters) - AstraZeneca will start clinical trials to
test a combination of its experimental COVID-19 vaccine with
Russia's Sputnik V shot aimed at boosting the efficacy of the
British drugmaker's vaccine, Russia's sovereign wealth fund said
on Friday.

Trials will start by the end of the year and Russia wants to
jointly produce the new vaccine if it is proven to be effective,
said the RDIF wealth fund, which has funded Sputnik V, named
after the Soviet-era satellite that triggered the space race.

AstraZeneca, in a statement on Friday, said it was
considering how it could assess combinations of different
vaccines, and would soon begin exploring with Russia's Gamaleya
Institute, which developed Sputnik V, whether two common cold
virus-based vaccines could be successfully combined.

It did not give further details. However, its Russian arm
said it would start to enrol adults aged 18 years and older for
the trial.

The co-operation between one of Britain's most valuable
listed companies and the state-backed Russian science research
institute highlights the pressure to develop an effective shot
to fight the pandemic that has killed over 1.5 million people.

The move is likely to be seen in Moscow as a long-awaited
vote of confidence by a Western manufacturer in Sputnik V.

Its Russian developers say clinical trials, still underway,
have shown it has an efficacy rate of over 90%, higher than
AstraZeneca's own vaccine and similar to U.S. rivals Pfizer
and Moderna.

Some Western scientists have raised concerns about the speed
at which Russia has worked, giving the regulatory go-ahead for
its vaccines and launching large-scale vaccinations with Sputnik
V before full trials to test its safety and efficacy have been
completed. Russia has rejected such criticism as unfounded.

The prospective tie-up comes as AstraZeneca, once seen as a
frontrunner in the vaccine race, prepares for further tests to
confirm whether its shot could be 90% effective, potentially
slowing its roll out.

The average efficacy rate was 70.4% in interim late-stage
data.

TWITTER DIPLOMACY

The partnership came about after the developers of Sputnik V
suggested on Twitter last month that AstraZeneca try the
combination after the British drugmaker released interim results
from its late-stage trial.

The British drugmaker accepted the proposal, the RDIF said
on Friday.

"The decision by AstraZeneca to carry out clinical trials
using one of two vectors of Sputnik V in order to increase its
own vaccine’s efficacy is an important step towards uniting
efforts in the fight against the pandemic," said RDIF head
Kirill Dmitriev in a statement.

"We hope that other vaccine producers will follow our
example."

Earlier this week, Kate Bingham, chair of Britain's vaccine
task force, said the country would start trials next year using
combinations of different kinds of vaccine for the initial and
booster vaccinations, in the hope that a "mix-and-match"
approach might maximise the immune response.

Both projects are using harmless adenoviruses as vehicles to
bring genetic instructions into the body to prompt cells to
produce vaccine proteins, an approach that has previously been
used in an Ebola vaccine.

One common challenge of such a method is that the immune
system could attack the adenovirus vehicle, known as the viral
vector, and in particular neutralise the staggered booster shot
that is now an important feature of the leading COVID-19 vaccine
candidates.

Using different viral vectors for the primer and booster
shot is one approach that researchers, including at the Gamaleya
Institute, have pursued. Combining vaccines from different
developers could also be a way around that.

AstraZeneca and partner Oxford University have used a
harmless adenovirus only found in monkeys to rule out that
people receiving the shot had previous exposure and therefore an
immune defence against it.

AstraZeneca did not mention immunity against the viral
vector as an issue in its statement on Friday.

Still, Russian officials have not always been complimentary
about the British vaccine.

When the company paused a clinical trial in September due to
the unexplained illness of a volunteer, Kremlin spokesman Dmitry
Peskov told reporters that Sputnik V was a more reliable vaccine
because it was based on an adenovirus found in humans, whereas
the British candidate was "a monkey vaccine."

The partnership may draw scrutiny after Britain said in July
hackers backed by the Russian state were trying to steal
COVID-19 vaccine and treatment research from academic and
pharmaceutical institutions around the world. The Kremlin
rejected the Western allegations.

The news came as Sanofi and GlaxoSmithKline
said clinical trials of their COVID-19 vaccine showed an
insufficient immune response in older people.

(Reporting by Pushkala Aripaka in Bengaluru and Andrew Osborn
in Moscow; Additional reporting by Ludwig Burger
Writing by Josephine Mason;
editing by Patrick Graham and Mark Potter)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.